350 related articles for article (PubMed ID: 34503105)
1. Immune-Omics Networks of
Ye Q; Singh S; Qian PR; Guo NL
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503105
[TBL] [Abstract][Full Text] [Related]
2. Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks.
Ye Q; Guo NL
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551208
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer.
Ye Q; Falatovich B; Singh S; Ivanov AV; Eubank TD; Guo NL
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008645
[TBL] [Abstract][Full Text] [Related]
4. Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data.
Ye Q; Putila J; Raese R; Dong C; Qian Y; Dowlati A; Guo NL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299277
[TBL] [Abstract][Full Text] [Related]
5. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
Guo NL; Dowlati A; Raese RA; Dong C; Chen G; Beer DG; Shaffer J; Singh S; Bokhary U; Liu L; Howington J; Hensing T; Qian Y
EBioMedicine; 2018 Jun; 32():102-110. PubMed ID: 29861409
[TBL] [Abstract][Full Text] [Related]
6. Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors.
Ye Q; Guo NL
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804895
[TBL] [Abstract][Full Text] [Related]
7. Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival.
Ye Q; Hickey J; Summers K; Falatovich B; Gencheva M; Eubank TD; Ivanov AV; Guo NL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499305
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
9.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
10. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A; Finetti P; Denicolai E; Greillier L; Boudou-Rouquette P; Goldwasser F; Lumet G; Ceccarelli M; Birnbaum D; Bedognetti D; Mamessier E; Barlesi F; Bertucci F; Tomasini P
J Transl Med; 2023 Sep; 21(1):637. PubMed ID: 37726776
[TBL] [Abstract][Full Text] [Related]
11. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.
Wu Y; Lin L; Liu X
Dis Markers; 2020; 2020():7291586. PubMed ID: 32587640
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy.
Ye Z; Huang T; Hu K; Zhou H; Huang L; Wang L
J Appl Genet; 2024 Feb; ():. PubMed ID: 38363451
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
14. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
Wang L; Ren Z; Yu B; Tang J
J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer.
Zheng Y; Tang L; Liu Z
BMC Cancer; 2021 Dec; 21(1):1322. PubMed ID: 34893051
[TBL] [Abstract][Full Text] [Related]
16. PDL1 Regulation by p53 via miR-34.
Cortez MA; Ivan C; Valdecanas D; Wang X; Peltier HJ; Ye Y; Araujo L; Carbone DP; Shilo K; Giri DK; Kelnar K; Martin D; Komaki R; Gomez DR; Krishnan S; Calin GA; Bader AG; Welsh JW
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26577528
[TBL] [Abstract][Full Text] [Related]
17. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
18. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
19. Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.
Ma Q; Geng K; Xiao P; Zeng L
Biomed Res Int; 2021; 2021():5963868. PubMed ID: 34518802
[TBL] [Abstract][Full Text] [Related]
20. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
